Abstract
Lifileucel or TIL has recently been FDA approved for metastatic melanoma patients as first cell therapy for a solid tumor. We discuss roll-out of TIL as new SOC and other upcoming new cell therapies.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Full text links